Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation

American Journal of Nephrology

Volumn 31, Issue 6, 2010, Pages 482-489

  Borchhardt, Kyra A ^a   Diarra, Danielle ^a   Sulzbacher, Irene ^a   Benesch, Thomas ^a   Haas, Martin ^a   Sunder Plassmann, Gere ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bone density; Bone formation rate; Bone histomorphometry; Bone turnover; Cinacalcet; Hypercalcemia; Hyperparathyroidism; Kidney transplantation

Indexed keywords

CALCIFEDIOL; CALCITONIN; CALCITRIOL; CALCIUM; CINACALCET; CYCLOSPORIN A; DOXYCYCLINE; EVEROLIMUS; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARATHYROID HORMONE; RAPAMYCIN; STEROID; TACROLIMUS; NAPHTHALENE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE DISEASE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; FEMUR; FRACTURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; HYPERPARATHYROIDISM; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MORPHOMETRICS; OSSIFICATION; OSTEOBLAST; OSTEOID; PRIORITY JOURNAL; TRABECULAR BONE; BONE DEVELOPMENT; DRUG EFFECTS; HYPERKALEMIA; MIDDLE AGED; TREATMENT OUTCOME;

AGED; BONE DENSITY; FEMALE; HUMANS; HYPERKALEMIA; HYPERPARATHYROIDISM; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NAPHTHALENES; OSTEOGENESIS; TREATMENT OUTCOME;

EID: 77951534081     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000304180     Document Type: Article

References (44)

1. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G: Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953. (Pubitemid 43924257)
2. Weisinger JR, Carlini RG, Rojas E, Bellorin-Font E: Bone disease after renal transplantation. Clin J Am Soc Nephrol 2006; 1: 1300-1313.
3. D'Alessandro AM, Melzer JS, Pirsch JD, Sollinger HW, Kalayoglu M, Vernon WB, Belzer FO, Starling JR: Tertiary hyperparathyroidism after renal transplantation: operative indications. Surgery 1989; 106: 1049-11046
4. Evenepoel P, Claes K, Kuypers D, Maes B, Vanrenterghem Y: Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single-centre study. Nephrol Dial Transplant 2005; 20: 1714-1720.
5. Gwinner W, Suppa S, Mengel M, Hoy L, Kreipe HH, Haller H, Schwarz A: Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005; 5: 1934-1941.
6. Borchhardt K, Sulzbacher I, Benesch T, Födinger M, Sunder-Plassmann G, Haas M: Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Transplant 2007; 7: 2515-2521.
7. Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG: The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1311-1314.
8. Leca N, Laftavi M, Gundroo A, Kohli R, Min I, Karam J, Sridhar N, Blessios G, Venuto R, Pankewycz O: Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am J Transplant 2006; 6: 2391-2395.
9. Serra AL, Schwarz AA, Wick FH, Marti HP, Wüthrich RP: Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1315-1319.
10. Srinivas TR, Schold JD, Womer KL, Kaplan B, Howard RJ, Bucci CM, Meier-Kriesche HU: Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 2006; 1: 323-326.
11. Szwarc I, Argiles A, Garrigue V, Delmas S, Chong G, Deleuze S, Mourad G: Cinacalcet chloride is efficient and safe in renal transplant recipients with post-transplant hyperparathyroidism. Transplantation 2006; 82: 675-680.
12. El-Amm JM, Doshi MD, Singh A, Migdal S, Morawski K, Sternbauer D, Cincotta E, West MS, Losanoff JE, Gruber SA: Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 2007; 83: 546-549.
13. Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG: Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2007; 22: 2362-2365.
14. Borchhardt KA, Heinzl H, Mayerwöger E, Hörl WH, Haas M, Sunder-Plassmann G: Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation 2008; 86: 919-924.
15. Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C, Steininger R, Grampp S, Klaushofer K, Delling G, et al: Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 2003; 63: 1130-1136.
16. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR: Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2: 595-610.
17. Aaron JB, Silverman SH, Halperin J: Fetal survival in twin delivery. Am J Obstet Gynecol 1961; 81: 331-334.
18. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(suppl 3):S1-S201.
19. Yajima A, Inaba M, Tominaga Y, Ito A: Bone formation by minimodeling is more active than remodeling after parathyroidectomy. Kidney Int 2008; 74: 775-781.
20. Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, et al: An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 2008; 69: 269-278.
21. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM: Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800.
22. Bergua C, Torregrosa JV, Fuster D, Gutierrez-Dalmau A, Oppenheimer F, Campistol JM: Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation 2008; 86: 413-417.
23. Malluche HH, Mawad H, Monier-Faugere MC: Effects of treatment of renal osteodystrophy on bone histology. Clin J Am Soc Nephrol 2008; 3(suppl 3):S157-S163.
24. Baker LR, Abrams L, Roe CJ, Faugere MC, Fanti P, Subayti Y, Malluche HH: 1,25(OH) 2 D 3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int 1989; 35: 661-669.
25. Parfitt AM: Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens 2003; 12: 387-403.
26. Carlini RG, Rojas E, Weisinger JR, Lopez M, Martinis R, Arminio A, Bellorin-Font E: Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis 2000; 36: 160-166.
27. Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH: High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 2000; 11: 1093-1099.
28. Schmitt CP, Huber D, Mehls O, Maiwald J, Stein G, Veldhuis JD, Ritz E, Schaefer F: Altered instantaneous and calcium-modulated oscillatory PTH secretion patterns in patients with secondary hyperparathyroidism. J Am Soc Nephrol 1998; 9: 1832-1844.
29. Iwasaki Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, Hosokawa A, Motojima M, Fukagawa M: Insufficiency of PTH action on bone in uremia. Kidney Int Suppl 2006; 102:S34-S36.
30. El-Hajj Fuleihan G, Klerman EB, Brown EN, Choe Y, Brown EM, Czeisler CA: The parathyroid hormone circadian rhythm is truly endogenous - a general clinical research center study. J Clin Endocrinol Metab 1997; 82: 281-286.
31. Kamar N, Gennero I, Spataru L, Esposito L, Guitard J, Lavayssiere L, Cointault O, Gandia P, Durand D, Rostaing L: Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose. Nephrol Dial Transplant 2008; 23: 3720-3726.
32. Ritz E: Calcimimetics - fooling the calcium receptor. Pediatr Nephrol 2005; 20: 15-18.
33. Ott SM: Histomorphometric measurements of bone turnover, mineralization, and volume. Clin J Am Soc Nephrol 2008; 3(suppl 3):S151-S156.
34. Dos Reis LM, Batalha JR, Munoz DR, Borelli A, Correa PH, Carvalho AB, Jorgetti V: Brazilian normal static bone histomorphometry: effects of age, sex, and race. J Bone Miner Metab 2007; 25: 400-406.
35. Schober HC, Han ZH, Foldes AJ, Shih MS, Rao DS, Balena R, Parfitt AM: Mineralized bone loss at different sites in dialysis patients: implications for prevention. J Am Soc Nephrol 1998; 9: 1225-1233.
36. Leonard MB: A structural approach to the assessment of fracture risk in children and adolescents with chronic kidney disease. Pediatr Nephrol 2007; 22: 1815-1824.
37. Steiniche T: Bone histomorphometry in the pathophysiological evaluation of primary and secondary osteoporosis and various treatment modalities. APMIS Suppl 1995; 51: 1-44.
38. Nickolas TL, Leonard MB, Shane E: Chronic kidney disease and bone fracture: a growing concern. Kidney Int 2008; 74: 721-731.
39. Borchhardt KA, Hörl WH, Sunder-Plassmann G: Reversibility of 'secondary hypercalcitoninemia' after kidney transplantation. Am J Transplant 2005; 5: 1757-1763.
40. Abdallah KA, Jorgetti V, Pereira RC, Reis LM, Pereira LM, Correa PH, Borelli A, Ianhez LE, Moyses RM, David-Neto E: Improvement of adynamic bone disease after renal transplantation. Braz J Med Biol Res 2006; 39: 31-41. (Pubitemid 43091527)
41. Sanchez CP, Salusky IB, Kuizon BD, Ramirez JA, Gales B, Ettenger RB, Goodman WG: Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int 1998; 53: 1358-1364.
42. Cejka D, Benesch T, Krestan C, Roschger P, Klaushofer K, Pietschmann P, Haas M: Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant 2008; 8: 1864-1870.
43. Montalban C, de Francisco AL, Marinoso ML, Zubimendi JA, Garcia Unzueta M, Amado JA, Arias M: Bone disease in longterm adult kidney transplant patients with normal renal function. Kidney Int Suppl 2003; 85:S129-S132.
44. Cueto-Manzano AM, Konel S, Crowley V, France MW, Freemont AJ, Adams JE, Mawer B, Gokal R, Hutchison AJ: Bone histopathology and densitometry comparison between cyclosporine a monotherapy and prednisolone plus azathioprine dual immunosuppression in renal transplant patients. Transplantation 2003; 75: 2053-2058.